Sample result
A saved result, shown read-only. Sign in to run your own searches. A new account gets a free 30-day trial.
GLP-1, a diabetes hormone
Protein → Patent proteins · Automatic (Smith-Waterman)
Every list and the search record, one sheet each.
- Query
- GLP-1 · 31 lettersHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG
- Set
- Public patent sequences: Patent proteins, snapshot 2026-11-05-c456f6bdba29
- Ran
- 2026-11-12
- Found
- 5,000 sequences, 3,061 publications, 1,851 families
Charts
Identity against coverage
5,000 hits by identity and query coverage. 5,000 with a date.
Show table
| Band | Has a date | All |
|---|---|---|
| 100% | 553 | 553 |
| 95 to 99.9% | 992 | 992 |
| 90 to 94.9% | 2,638 | 2,638 |
| 80 to 89.9% | 814 | 814 |
| 70 to 79.9% | 3 | 3 |
| Band | Has a date | All |
|---|---|---|
| 100% | 3,606 | 3,606 |
| 95 to 99.9% | 876 | 876 |
| 90 to 94.9% | 483 | 483 |
| 80 to 89.9% | 35 | 35 |
Hits by year
3,061 publications by year of first publication, 1990 to 2026.
Show table
| Year | Has a date | All |
|---|---|---|
| 1990 | 2 | 2 |
| 1992 | 2 | 2 |
| 1993 | 1 | 1 |
| 1994 | 1 | 1 |
| 1995 | 1 | 1 |
| 1996 | 3 | 3 |
| 1997 | 2 | 2 |
| 1998 | 2 | 2 |
| 1999 | 11 | 11 |
| 2000 | 13 | 13 |
| 2001 | 20 | 20 |
| 2002 | 37 | 37 |
| 2003 | 33 | 33 |
| 2004 | 37 | 37 |
| 2005 | 54 | 54 |
| 2006 | 62 | 62 |
| 2007 | 77 | 77 |
| 2008 | 81 | 81 |
| 2009 | 107 | 107 |
| 2010 | 101 | 101 |
| 2011 | 110 | 110 |
| 2012 | 121 | 121 |
| 2013 | 123 | 123 |
| 2014 | 135 | 135 |
| 2015 | 142 | 142 |
| 2016 | 144 | 144 |
| 2017 | 157 | 157 |
| 2018 | 149 | 149 |
| 2019 | 150 | 150 |
| 2020 | 156 | 156 |
| 2021 | 183 | 183 |
| 2022 | 161 | 161 |
| 2023 | 175 | 175 |
| 2024 | 181 | 181 |
| 2025 | 231 | 231 |
| 2026 | 96 | 96 |
Where hits align on the query
The top 20 hits on GLP-1, a query of 31 amino acids: 20 cover the whole query, none differs from it.
Show table
| Hit | Query from | Query to | Identity | Differs at | Gaps at | X at |
|---|---|---|---|---|---|---|
| AAA55132.1 | 1 | 31 | 100.0% | None | None | None |
| A31422.1 | 1 | 31 | 100.0% | None | None | None |
| AAB11984.1 | 1 | 31 | 100.0% | None | None | None |
| DI506186 | 1 | 31 | 100.0% | None | None | None |
| DI527435 | 1 | 31 | 100.0% | None | None | None |
| AAB11995.1 | 1 | 31 | 100.0% | None | None | None |
| AAE02614.1 | 1 | 31 | 100.0% | None | None | None |
| DI540976 | 1 | 31 | 100.0% | None | None | None |
| DI521338 | 1 | 31 | 100.0% | None | None | None |
| DI502216 | 1 | 31 | 100.0% | None | None | None |
| DJ789879 | 1 | 31 | 100.0% | None | None | None |
| DI520483 | 1 | 31 | 100.0% | None | None | None |
| AAE49428.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49430.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49429.1 | 1 | 31 | 100.0% | None | None | None |
| AAE49432.1 | 1 | 31 | 100.0% | None | None | None |
| DI501808 | 1 | 31 | 100.0% | None | None | None |
| AAY78103.1 | 1 | 31 | 100.0% | None | None | None |
| BD613525 | 1 | 31 | 100.0% | None | None | None |
| BD613528 | 1 | 31 | 100.0% | None | None | None |
Patents 3.1K
3,061 publications from 692 applicants, 83 with no applicant, match these filters.
Eli Lilly and Company 205 publications, continued
-
JP 2004521093-A2004-07-15
CHRONIC TREATMENT REGIMEN USING GLUCAGON-LIKE INSULINOTROPIC PEPTIDES
Eli Lilly and Company
Query Match 93.8%Identity 96.7%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 | |||||||||||||||||||||||||||| Hit 1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3029 of 30 identical, no gaps.
-
US 7259233-A2007-08-21
Chronic treatment regimen using glucagon-like insulinotropic peptides
Eli Lilly and Company
Query Match 93.8%Identity 96.7%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 | |||||||||||||||||||||||||||| Hit 1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3029 of 30 identical, no gaps.
-
EP 2186824-A22010-05-19
Chronic treatment regimen using glucagon-like insulinotropic peptides
Eli Lilly & Company (US)
Query Match 93.8%Identity 96.7%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 | |||||||||||||||||||||||||||| Hit 1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3029 of 30 identical, no gaps.
-
US 7989585-B22011-08-02
Chronic treatment regimen using glucagon-like insulinotropic peptides
Eli Lilly and Company
Query Match 93.8%Identity 96.7%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 | |||||||||||||||||||||||||||| Hit 1 HGEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3029 of 30 identical, no gaps.
-
JP 2005530732-A2005-10-13
TREATMENT OF GASTROPARESIS
Eli Lilly and Company
Query Match 93.2%Identity 100.0%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29 ||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 2929 of 29 identical, no gaps.
-
KR 1020210071038-A2021-06-15
PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
US 11155592-B22021-10-26
Protein tyrosine-tyrosine analogs and methods of using the same
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
JP 2022506070-A2022-01-17
PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
JP 2023082013-A2023-06-13
PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
US 11820803-B22023-11-21
Protein tyrosine-tyrosine analogs and methods of using the same
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
KR 1020240093737-A2024-06-24
PROTEIN TYROSINE-TYROSINE ANALOGS AND METHODS OF USING THE SAME
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
US 12269857-B22025-04-08
Protein tyrosine-tyrosine analogs and methods of using the same
Eli Lilly and Company
Query Match 92.5%Identity 93.5%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||||| Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG 3129 of 31 identical, no gaps.
-
JP 2002532557-A2002-10-02
Shelf-stable formulation of glucagon-like peptide-1
ELI LILLY AND CO
Query Match 90.1%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | |||||||||||| ||||| |||||||||| Hit 1 HXEGTFTSDVSSYLXGQAAKXFIAWLVKGRG 3128 of 31 identical, no gaps.
-
EP 1600162-A12005-11-30
Shelf-stable formulation of glucagon-like peptide-1
Eli Lilly & Company (US)
Query Match 90.1%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | |||||||||||| ||||| |||||||||| Hit 1 HXEGTFTSDVSSYLXGQAAKXFIAWLVKGRG 3128 of 31 identical, no gaps.
-
WO 2009009562-A12009-01-15
Glp-1-fc fusion protein formulation
ELI LILLY AND COMPANY (US)
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020100020516-A2010-02-22
GLP-1-FC FUSION PROTEIN FORMULATION
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020200076705-A2020-06-29
METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2020521765-A2020-07-27
Therapeutic Uses of Dulaglutide
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2021502379-A2021-01-28
Methods of Using and Compositions Containing Dulaglutide
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020210134713-A2021-11-10
THERAPEUTIC USES OF DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2022525883-A2022-05-20
Preserved Formulations
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020220132606-A2022-09-30
THERAPEUTIC USES OF DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020220146656-A2022-11-01
METHODS OF USING AND COMPOSITIONS CONTAINING DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2023002547-A2023-01-10
Dulaglutide for the treatment of chronic kidney disease
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2023513054-A2023-03-30
Therapeutic Uses of Dulaglutide
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2023123742-A2023-09-05
Preserved Formulations
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020230132627-A2023-09-15
THERAPEUTIC USES OF DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
US 11890325-B22024-02-06
Therapeutic uses of dulaglutide
ELI LILLY AND COMPANY
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
JP 2025000602-A2025-01-07
Therapeutic Uses of Dulaglutide
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020250005518-A2025-01-09
THERAPEUTIC USES OF DULAGLUTIDE
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
KR 1020250128374-A2025-08-27
METHODS OF DULAGLUTIDE PURIFICATION USING HYDROPHOBIC INTERACTION CHROMATOGRAPHY
Eli Lilly and Company
Query Match 88.2%Identity 90.3%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 | ||||||||||||| ||||||||||||| | Hit 1 HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGG 3128 of 31 identical, no gaps.
-
EP 1227151-A12002-07-31
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ELI LILLY AND COMPANY (US)
Query Match 87.6%Identity 96.6%
Best alignment
Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.
Query 2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||| |||||||||| Hit 2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 3028 of 29 identical, no gaps.
-
US 6573237-A2003-06-03
Protein formulations
Eli Lilly and Company
Query Match 87.6%Identity 100.0%
Best alignment
Query 2 to 30, hit 2 to 30. Positions start at 1 and include both ends.
Query 2 AEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||| |||||||||| Hit 2 AEGTFTSDVSSYLEGQAAXEFIAWLVKGR 3028 of 29 identical, no gaps.
-
WO 2006124529-A12006-11-23
Glp-1 pegylated compounds
Eli Lilly and Company (US)
Query Match 83.2%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29 | ||||||||||||| |||||||||| || Hit 1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 2926 of 29 identical, no gaps.
-
JP 2008540565-A2008-11-20
GLP-1 Pegylated Compounds
Eli Lilly and Company
Query Match 83.2%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29 | ||||||||||||| |||||||||| || Hit 1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 2926 of 29 identical, no gaps.
-
US 8183340-B22012-05-22
GLP-1 pegylated compounds
Eli Lilly and Company
Query Match 83.2%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29 | ||||||||||||| |||||||||| || Hit 1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 2926 of 29 identical, no gaps.
-
JP 2013079256-A2013-05-02
GLP-1 Pegylated Compounds
Eli Lilly and Company
Query Match 83.2%Identity 89.7%
Best alignment
Query 1 to 29, hit 1 to 29. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKG 29 | ||||||||||||| |||||||||| || Hit 1 HXEGTFTSDVSSYLEXQAAKEFIAWLXKG 2926 of 29 identical, no gaps.
CARLSBERG LABORATORY 1 publication
-
JP 2001513638-A2001-09-04
Modified carboxypeptidase
CARLSBERG LABORATORY
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
ITOHAM FOODS INC 1 publication
-
JP 2001278807-A2001-10-10
Enterokinesis inhibitor
ITOHAM FOODS INC
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 7 to 36. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 7 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3630 of 30 identical, no gaps.
Theratechnologies Inc. (CA) 8 publications
-
WO 0210195-A22002-02-07
Modified peptides with increased potency
THERATECHNOLOGIES INC. (CA)
Query Match 100.0%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 3131 of 31 identical, no gaps.
-
JP 2004509079-A2004-03-25
MODIFIED BIOLOGICAL PEPTIDES WITH INCREASED POTENCY
THERATECHNOLOGIES INC
Query Match 100.0%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 3131 of 31 identical, no gaps.
-
WO 2004029081-A22004-04-08
Modified glp-1 peptides with increased biological potency
Theratechnologies Inc. (CA)
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
WO 2004111078-A22004-12-23
Compounds that modulate the glucagon response and uses thereof
Theratechnologies Inc. (CA)
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 7067488-A2006-06-27
Modified GLP-1 peptides with increased biological potency
TheraTechnologies Inc.
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
EP 1709071-A12006-10-11
Glucagon-like peptide-1 analogs with long duration of action
THERATECHNOLOGIES INC
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
US 7538185-A2009-05-26
Glucagon-like peptide-1 analogs with long duration of action
Theratechnologies Inc.
Query Match 96.3%Identity 100.0%
Best alignment
Query 1 to 30, hit 1 to 30. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 30 |||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR 3030 of 30 identical, no gaps.
-
WO 2004067548-A22004-08-12
Chemically modified metabolites of regulatory peptides and methods of producing and using same
THERATECHNOLOGIES INC. (CA)
Query Match 92.5%Identity 100.0%
Best alignment
Query 3 to 31, hit 1 to 29. Positions start at 1 and include both ends.
Query 3 EGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||| Hit 1 EGTFTSDVSSYLEGQAAKEFIAWLVKGRG 2929 of 29 identical, no gaps.
Novo Nordisk A/S 299 publications
-
JP 2002512175-A2002-04-23
Derivatives of GLP-1 analogues
NOVO NORDISK AS
Query Match 100.0%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 3131 of 31 identical, no gaps.
-
JP 2003520571-A2003-07-08
Pectate lyase fusion for expression and secretion of polypeptides.
Novo Nordisk A/S
Query Match 100.0%Identity 100.0%
Best alignment
Query 1 to 31, hit 348 to 378. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||||| Hit 348 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 37831 of 31 identical, no gaps.
-
JP 2003525908-A2003-09-02
Lowering serum lipids
Novo Nordisk A/S
Query Match 100.0%Identity 100.0%
Best alignment
Query 1 to 31, hit 1 to 31. Positions start at 1 and include both ends.
Query 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 31 ||||||||||||||||||||||||||||||| Hit 1 HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG 3131 of 31 identical, no gaps.